Scientists have developed a breathalyzer to diagnose 17 diseases with one breath from a patient
Royal physicians were known to sniff noblemen’s excrements
as a test for disease. That may sound disgusting, but modern science
backs the idea that certain diseases cause the body to produce volatile
compounds, which if detected properly could provide a powerful
diagnostic method.
In the last 10 years, researchers have developed specific sniff tests
for diagnosing tuberculosis, hypertension, cystic fibrosis, and even
certain types of cancer. Here’s how it works: cystic fibrosis, for
instance, causes patient’s bodies to function such that they produce nearly four times as much acetic acid (the base chemical in vinegar) as healthy people.
Now a group of global researchers led by Hossam Haick at the Israel
Institute of Technology have taken the idea a step further. They’ve
built a device—a kind of breathalyzer—that is compact and can diagnose
up to 17 diseases from a single breath of a patient.
The breathalyzer has an array of specially created gold
nanoparticles, which are sized at billionths of a meter, and mixed with
similar-sized tubes of carbon. These together create a network that is
able to interact differently with each of the nearly 100 volatile
compounds that each person breaths out (apart from gases like nitrogen,
oxygen, and carbon dioxide).
Haick’s team collected 2,800 breaths from more than 1,400 patients
who were each suffering from at least one of 17 diseases (in three
classes: cancer, inflammation, and neurological disorders). Each sample
of the disease was then passed through the special breathalyzer, which
then produced a dataset of the types of chemicals it could detect and in
roughly what quantities.
The team then applied artificial intelligence to the dataset to
search for patterns in the types of compounds detected and the
concentrations they were detected at. As they report in the journal ACS Nano,
the data from the breathalyzer could be used to accurately detect that a
person is suffering from a unique disease nearly nine out of ten times.
Each of the diseases, ranging from kidney cancer to multiple
sclerosis, had its own unique “breathprint.” Further analysis of the
samples also revealed that, among the 100 or so volatile chemicals in a
breath, variations in the levels of only 13 of them were key to disease
detection.
The accuracy of the new breathalyzer is not yet at a level where it
can be deployed in clinical settings. The success rate needs to be
nearer to 99% rather than the current 86% for that. But as a
proof-of-concept device, which is both compact and inexpensive, it’s a
big step forward. And potentially, it could put a centuries-old idea
into practical use.
ANAΔΗΜΟΣΙΕΥΣΗ ΑΠΟ ΤΟ FUTURESCOPE.COM 26/1/2017
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου